To determine whether the amelioration of hepatic lipid deposition by Cori treatment via autophagy activation, we next examined the protein expression levels of LC3 and p62 in our established model of NAFLD in vitro. This evidence concerns the gene MAP1LC3A and metabolic dysfunction-associated steatotic liver disease.